Ghent University and the booming Ghent biotech landscape welcome a brand new spin-off: Amalus Therapeutics is developing a new class of drugs that selectively target corrupt fibroblast cells.
Eight new companies have joined The BioInnovation Institute’s (BII’s) Venture Lab acceleration program for early-stage companies, it was announced today (August 31).